WCM 2017 Highlights: Immunotherapy


November 1, 2017

  • Share this post:

The 9th World Congress of Melanoma (WCM) was held in Brisbane, Australia, from 18 to 21 October. In a series of interviews medical professionals from all over the world discussed the latest developments in the field of melanoma.

This highlight consists of the following parts:

  • Prof. Caroline Robert, MD – dermatologist, Institute Gustave-Roussy, Paris, France: The latest results of immunotherapy in melanoma
  • Alain Algazi, MD – oncologist, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA: Clinical immune monitoring and biomarker data of pIL-12 monotherapy compared to pIL-12 with pembrolizumab in metastatic melanoma
  • Sapna Patel, MD – oncologist, MD Anderson Cancer Center, Houston, USA: A phase II study of glembatumumab vedotin for metastatic uveal melanoma

The interviews are editorially independent and are financially supported by BMS, Incyte, MSD and Novartis.

Related articles